Depomed, Inc. has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. NUCYNTA is now the flagship asset in Depomed’s growing portfolio of pain and neurological specialty pharmaceuticals.
According to the terms of the agreement, Depomed will begin shipping NUCYNTA the week of April 6, reflecting a price adjustment made after closing the deal. Quintiles, the contract sales organization that promoted the NUCYNTA franchise for Janssen, will continue to support these products for Depomed until re-launch in June.
Source: Depomed
